[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hangzhou Dinova EP Technology Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,69,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100639507","a-study-on-the-therapeutic-value-of-additional-left-atrial-posterior-wall-isolation-guided-by-voltage-mapping-in-persistent-atrial-fibrillation-100639507",false,"NCT07590661","A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.","Prospective, Multicenter, Randomized Controlled Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.","Inclusion Criteria:\n\n1. Older than 18 years.\n2. Diagnosed as persistent atrial fibrillation (AF); Definition: At least one episode of persistent AF was recorded on dynamic electrocardiogram (ECG) data within 12 months prior to enrollment, or other clinical evidence supporting persistent AF episodes lasting more than 7 days.\n3. Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.\n\nExclusion Criteria:\n\n1. Atrial fibrillation is secondary to thyroid disease or other reversible factors.\n2. Evidence of left atrial or left atrial appendage thrombus on imaging examination.\n3. Rheumatic heart disease or the presence of moderate to severe mitral stenosis or regurgitation.\n4. Left ventricular ejection fraction \\\u003C40% or New York Heart Association (NYHA) class III\u002FIV.\n5. Left atrial anteroposterior diameter \\>55 mm.\n6. Unstable angina.\n7. Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 3 months prior to enrollment.\n8. Previous catheter ablation or surgical ablation for atrial fibrillation.\n9. History of prior left atrial appendage closure, patent foramen ovale closure, atrial septal defect closure, or repair surgery.\n10. Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings.\n11. Presence of intracardiac thrombus, space-occupying lesions, or other abnormalities that preclude vascular access or catheter manipulation.\n12. Contraindications to anticoagulation or history of coagulation disorders\u002Fabnormal bleeding.\n13. Active systemic infection.\n14. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² or history of renal dialysis.\n15. Severe hepatic dysfunction.\n16. Pregnancy or breastfeeding.\n17. Life expectancy \\\u003C12 months (e.g., advanced malignancy).\n18. Current or anticipated participation in other drug or device clinical trials.\n19. Any other condition or abnormality deemed by the investigator to warrant exclusion.",true,"ALL","18 Years",{"count":20,"type":21},350,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substrate, pulmonary vein isolation combined with superior vena cava isolation will be performed. For those with abnormal left atrial substrate, two strategies will be adopted: pulmonary vein isolation plus superior vena cava isolation, and pulmonary vein isolation combined with superior vena cava isolation and left atrial posterior wall isolation. Long-term follow-up will be conducted to observe the long-term clinical outcomes.",[27],"Persistent Atrial Fibrillation","NOT_YET_RECRUITING","2026-05-12",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":34,"type":21},"2026-04-30",{"date":36,"type":21},"2029-02",{"name":38,"class":39},"Hangzhou Dinova EP Technology Co., Ltd","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":40},"100595785","comparison-of-different-pulsed-field-ablation-catheters-in-atrial-fibrillation-100595785","NCT07036965","Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation","Comparison of Different Pulsed Field Ablation Catheters Combined With Stroke Prevention in High Stroke Risk·Atrial Fibrillation: A Prospective, Multicenter, Randomized Controlled Trial","COMBINATION 2P","Inclusion Criteria:\n\n1. Older than 18 years.\n2. Diagnosed with drug-refractory, symptomatic atrial fibrillation.\n3. The patient has a high risk of stroke (CHA2DS2-VA score ≥ 2).\n4. Have a situation of:\n\n   1. requires oral anticoagulation therapy\n   2. high bleeding risk (HAS-BLED score ≥ 3) that unsuitable for or unwilling to undergo long-term oral anticoagulation therapy.\n5. Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.\n\nExclusion Criteria:\n\n1. History of persistent atrial fibrillation \\>1 year.\n2. Atrial fibrillation was secondary to thyroid disease or other reversible reasons.\n3. Left atrial anteroposterior diameter \\>50 mm.\n4. Evidence of left atrial or left atrial appendage thrombus on imaging examination.\n5. Concurrent other arrhythmias required for catheter ablation (e.g., atrioventricular reentrant tachycardia, atrioventricular nodal reentrant tachycardia, pre-excitation syndrome) prior to enrollment.\n6. Rheumatic heart disease.\n7. Left ventricular ejection fraction \\\u003C40% or New York Heart Association (NYHA) class III\u002FIV.\n8. Unstable angina.\n9. Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 3 months prior to enrollment.\n10. History of prior left atrial appendage closure, patent foramen ovale closure, atrial septal defect closure, or repair surgery.\n11. Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings.\n12. Presence of intracardiac thrombus, space-occupying lesions, or other abnormalities that preclude vascular access or catheter manipulation.\n13. Contraindications to anticoagulation or history of coagulation disorders\u002Fabnormal bleeding.\n14. Active systemic infection.\n15. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² or history of renal dialysis.\n16. Pregnancy or breastfeeding.\n17. Life expectancy \\\u003C12 months (e.g., advanced malignancy).\n18. Current or anticipated participation in other drug or device clinical trials.\n19. Any other condition or abnormality deemed by the investigator to warrant exclusion.","118 Years",{"count":51,"type":21},292,[24],"Pulsed field energy ablation, a non-thermal ablation modality, can potentially reduce post-ablation tissue edema. Previous studies have confirmed the feasibility and safety of combined pulsed field ablation (PFA) and left atrial appendage closure (LAAC) as a one-stop treatment, with few reports of post-ablation tissue edema. However, during PFA procedures, the presence of metallic components in the ablation site (e.g., occluder frames, metallic valves) may lead to arcing during energy delivery, compromising procedural safety. Therefore, when performing PFA+LAAC as a one-stop procedure, a \"ablation-first\" strategy is recommended. Due to the influence of parameters such as voltage, pulse width, and number of cycles on pulsed field energy characteristics, significant variability in ablation depth and area may exist between different PFA devices. To date, no large-scale clinical studies have compared the efficacy and safety of different PFA systems. Accordingly, this study will conduct a prospective, multicenter, randomized controlled trial to compare the effectiveness and safety of domestic versus imported pulsed field ablation catheters in the treatment of patients with atrial fibrillation.",[55],"Atrial Fibrillation (AF)",[57,58,59],"atrial fibrillation","pulsed field ablation","LAAC","RECRUITING","2025-06-17",{"date":63,"type":32},"2025-06-25",{"date":65,"type":21},"2025-06-30",{"date":67,"type":21},"2031-06-30",{"name":38,"class":39},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":87,"locationsCount":40},"100528182","an-exploratory-study-of-focal-pulse-ablation-system-in-the-treatment-of-atrial-arrhythmia-100528182","NCT06157437","An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia","Inclusion Criteria:\n\n* Subjects aged at least 18;\n* Subjects with at least one typical atrial flutter attack recorded by ECG or holter in the 180 days prior to enrollment, and the ECG of other hospitals could be accepted;\n* Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.\n\nExclusion Criteria:\n\n* Any prior cavo-tricuspid isthmus ablation;\n* Unstable angina;\n* Atrial flutter secondary to electrolyte disorder, thyroid disease or other reversible causes;\n* Myocardial infarction or coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within the prior three months;\n* At baseline, New York College of Cardiology (NYHA) heart function grades III and IV;\n* Implantable devices such as ICDs, CRTS and pacemakers in the body;\n* Atrial or ventricular tumors, blood clots, thrombus, or known clotting disorders were recorded within the prior 90 days;\n* Severe structural heart disease, including tricuspid stenosis, tricuspid malformation, or other congenital heart disease that prevents ablation surgery;\n* Previously received tricuspid metal valve replacement;\n* Thromboembolic events (including transient ischemic attacks) within the past 6 months;\n* Mural thrombosis, tumor, or other abnormality that interferes with vascular puncture or catheter operation;\n* Severe lung disease, pulmonary hypertension or any lung disease involving abnormal blood gas or severe breathing difficulties;\n* Anticoagulation contraindications and a history of blood clotting or abnormal bleeding;\n* Acute systemic infection;\n* Serum creatinine greater than twice the upper limit of normal, or any history of renal dialysis;\n* Women who are pregnant or breastfeeding or who cannot use contraception during the study period;\n* Enrollment in another clinical trial evaluating other devices or drugs during the same period;\n* Life expectancy less than 12 months (e.g. advanced malignancy);\n* Abnormalities or diseases considered by the investigator to be excluded from inclusion in this study.",{"count":76,"type":21},10,[24],"This is a prospective, single-group clinical study. The objective is to evaluate the safety and efficacy of focal pulse ablation system in the treatment of typical atrial flutter.",[80,55],"Typical Atrial Flutter","2025-02-07",{"date":83,"type":32},"2025-02-11",{"date":85,"type":32},"2023-12-01",{"date":65,"type":21},{"name":38,"class":39},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":40},"100466978","study-on-the-safety-and-effectiveness-of-the-snowytm-pfo-closure-system-100466978","NCT05360771","Study on the Safety and Effectiveness of the SnowyTM PFO Closure System","A Prospective, Multicenter, Randomized Controlled Clinical Study on the Safety and Effectiveness of the SnowyTM PFO Closure System in Plugging Patent Foramen Ovale","Inclusion Criteria:\n\n1. Age: 18 to 65 years old, regardless of gender\n2. Transthoracic echocardiographic contrast echocardiography (cTTE) confirmed the presence of PFO and at least moderate (see above definition) RLS (in Valsalva active\u002Fresting state)\n3. Existence of at least one of the following conditions： 1) Unexplained stroke or TIA 2) intractable or chronic migraine\n4. The subjects are informed of the nature of the study and agreed to all requirements for participation in the study, signed the informed consent form, and agree to complete the follow-up and follow-up examination\n\nExclusion Criteria:\n\n1. Patients have definite causes of stroke unrelated to the PFO\n2. RLS caused by other causes, such as atrial septal defect or pulmonary arteriovenous shunt\n3. Atrial fibrillation or atrial flutter\n4. Mitral and aortic stenosis or severe regurgitation\n5. Dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy\n6. Active endocarditis or other untreated infectious diseases\n7. Left ventricular ejection fraction (LVEF) \\\u003C 40%, or NYHA cardiac function grade III-IV\n8. Uncontrollable hypertension\n9. Previous intracardiac surgery\n10. Myocardial infarction or unstable angina pectoris within 6 months\n11. Contraindications to anticoagulants or antiplatelet drugs\n12. High risk of bleeding\n13. severe liver function impairment（alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal value）\n14. Serum creatinine greater than 2 times the upper limit of normal or with any history of renal dialysis or renal transplantation\n15. Severe pulmonary disease including pulmonary hypertension (clinical diagnosis)\n16. Nickel or contrast allergy\n17. Active or planned (within 12 months) pregnancy, or lactating female patients\n18. Malignant tumors or other serious diseases resulting in a life expectancy of less than 12 months\n19. Psychiatric conditions that may interfere with medical compliance and compliance with follow-up\n20. Concomitant participation in other clinical trials\n21. The investigator determines that the patient is unsuitable because of reasons not listed but thought to interfere with safe trial participation","65 Years",{"count":97,"type":21},242,[24],"To evaluate the safety and effectiveness of the SnowyTM PFO closure system in plugging patent foramen ovale",[101],"Patent Foramen Ovale","2023-06-05",{"date":104,"type":32},"2023-06-07",{"date":106,"type":21},"2023-10-20",{"date":108,"type":21},"2027-12-20",{"name":38,"class":39},""]